ELREXFIO Solution for injection Ref.[107897] Active ingredients: Elranatamab

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Product name and form

ELREXFIO 40 mg/mL solution for injection.

Pharmaceutical Form

Solution for injection (injection).

Clear to slightly opalescent, colourless to pale brownish solution, pH of 5.8, and osmolarity of approximately 301 mOsm/L.

Qualitative and quantitative composition

ELREXFIO 40 mg/mL solution for injection: One vial contains 44 mg of elranatamab in 1.1 mL (40 mg/mL).

ELREXFIO 40 mg/mL solution for injection: One vial contains 76 mg of elranatamab in 1.9 mL (40 mg/mL).

Elranatamab is an IgG2 kappa bispecific antibody derived from two monoclonal antibodies (mAbs). Elranatamab is produced using two recombinant Chinese hamster ovary (CHO) cell lines.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Elranatamab

Elranatamab is a bi-specific T-cell engaging antibody that binds CD3-epsilon on T-cells and B-cell maturation antigen (BCMA) on plasma cells, plasmablasts, and multiple myeloma cells. Binding of elranatamab to BCMA on tumour cells and CD3 on T-cells is independent of native T-cell receptor (TCR) specificity or reliance on major histocompatibility (MHC) Class 1 molecules. Elranatamab activated T-cells, led to proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.

List of Excipients

Edetate disodium
L-histidine
L-histidine hydrochloride monohydrate
Polysorbate 80
Sucrose
Water for injections

Pack sizes and marketing

ELREXFIO 40 mg/mL solution for injection: 1.1 mL solution in a vial (Type 1 glass) with a stopper (butyl rubber) and an aluminium seal with a flip-off cap containing 44 mg of elranatamab. Pack size of 1 vial.

ELREXFIO 40 mg/mL solution for injection: 1.9 mL solution in a vial (Type 1 glass) with a stopper (butyl rubber) and an aluminium seal with a flip-off cap containing 76 mg of elranatamab. Pack size of 1 vial.

Marketing authorization holder

Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Marketing authorization dates and numbers

EU/1/23/1770/001
EU/1/23/1770/002

Drugs

Drug Countries
ELREXFIO Austria, Estonia, France, Croatia, Lithuania, Romania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.